100 related articles for article (PubMed ID: 22213130)
1. Variations in the exome of the LNCaP prostate cancer cell line.
Spans L; Atak ZK; Van Nieuwerburgh F; Deforce D; Lerut E; Aerts S; Claessens F
Prostate; 2012 Sep; 72(12):1317-27. PubMed ID: 22213130
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
Vandamme T; Peeters M; Dogan F; Pauwels P; Van Assche E; Beyens M; Mortier G; Vandeweyer G; de Herder W; Van Camp G; Hofland LJ; Op de Beeck K
J Mol Endocrinol; 2015 Apr; 54(2):137-47. PubMed ID: 25612765
[TBL] [Abstract][Full Text] [Related]
3. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
4. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.
Leach FS; Velasco A; Hsieh JT; Sagalowsky AI; McConnell JD
J Urol; 2000 Nov; 164(5):1830-3. PubMed ID: 11025778
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach.
Bainbridge MN; Warren RL; Hirst M; Romanuik T; Zeng T; Go A; Delaney A; Griffith M; Hickenbotham M; Magrini V; Mardis ER; Sadar MD; Siddiqui AS; Marra MA; Jones SJ
BMC Genomics; 2006 Sep; 7():246. PubMed ID: 17010196
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
10. Exome versus transcriptome sequencing in identifying coding region variants.
Ku CS; Wu M; Cooper DN; Naidoo N; Pawitan Y; Pang B; Iacopetta B; Soong R
Expert Rev Mol Diagn; 2012 Apr; 12(3):241-51. PubMed ID: 22468815
[TBL] [Abstract][Full Text] [Related]
11. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme.
Kanai M; Ishii K; Kanda H; Ogura Y; Kise H; Arima K; Sugimura Y
Cancer Sci; 2008 Dec; 99(12):2435-43. PubMed ID: 19018772
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
13. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
14. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
16. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.
Cash J; Korchnak A; Gorman J; Tandon Y; Fraizer G
Oncol Rep; 2007 Jun; 17(6):1413-9. PubMed ID: 17487399
[TBL] [Abstract][Full Text] [Related]
17. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
19. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
